vs
Side-by-side financial comparison of BankUnited, Inc. (BKU) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
BankUnited, Inc. is the larger business by last-quarter revenue ($288.2M vs $158.6M, roughly 1.8× Stoke Therapeutics, Inc.). On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 9.0%).
BankUnited, Inc. is the bank holding company of BankUnited, N.A., a national bank founded in 1984 and headquartered in Miami Lakes, Florida. The company operates in Florida; the regions in and around Atlanta, Georgia; Dallas, Texas; Morristown, New Jersey; Charlotte, North Carolina; and in the New York metropolitan area. BankUnited also offers certain commercial lending and deposit products through national platforms and has total assets of $35.0 billion as of December 31, 2025
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
BKU vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $288.2M | $158.6M |
| Net Profit | — | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 31.2% | 70.2% |
| Net Margin | — | 71.2% |
| Revenue YoY | 9.0% | 3661.1% |
| Net Profit YoY | — | 528.0% |
| EPS (diluted) | $0.89 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $288.2M | — | ||
| Q3 25 | $275.7M | — | ||
| Q2 25 | $273.9M | — | ||
| Q1 25 | $255.4M | $158.6M | ||
| Q4 24 | $264.5M | $22.6M | ||
| Q3 24 | $257.0M | — | ||
| Q2 24 | $250.2M | — | ||
| Q1 24 | $241.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | $71.9M | — | ||
| Q2 25 | $68.8M | — | ||
| Q1 25 | $58.5M | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q3 24 | $61.5M | — | ||
| Q2 24 | $53.7M | — | ||
| Q1 24 | $48.0M | — |
| Q4 25 | 31.2% | — | ||
| Q3 25 | 35.5% | — | ||
| Q2 25 | 34.3% | — | ||
| Q1 25 | 31.4% | 70.2% | ||
| Q4 24 | 35.2% | -60.4% | ||
| Q3 24 | 32.4% | — | ||
| Q2 24 | 29.2% | — | ||
| Q1 24 | 27.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.1% | — | ||
| Q2 25 | 25.1% | — | ||
| Q1 25 | 22.9% | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q3 24 | 23.9% | — | ||
| Q2 24 | 21.5% | — | ||
| Q1 24 | 19.8% | — |
| Q4 25 | $0.89 | — | ||
| Q3 25 | $0.95 | — | ||
| Q2 25 | $0.91 | — | ||
| Q1 25 | $0.78 | $1.90 | ||
| Q4 24 | $0.91 | $-0.15 | ||
| Q3 24 | $0.81 | — | ||
| Q2 24 | $0.72 | — | ||
| Q1 24 | $0.64 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $217.8M | $274.8M |
| Total DebtLower is stronger | $319.7M | — |
| Stockholders' EquityBook value | $3.1B | $350.1M |
| Total Assets | $35.0B | $406.9M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $217.8M | — | ||
| Q3 25 | $559.5M | — | ||
| Q2 25 | $801.3M | — | ||
| Q1 25 | $443.7M | $274.8M | ||
| Q4 24 | $491.1M | $128.0M | ||
| Q3 24 | $889.9M | — | ||
| Q2 24 | $433.5M | — | ||
| Q1 24 | $421.2M | — |
| Q4 25 | $319.7M | — | ||
| Q3 25 | $320.4M | — | ||
| Q2 25 | $708.9M | — | ||
| Q1 25 | $709.1M | — | ||
| Q4 24 | $708.6M | — | ||
| Q3 24 | $708.7M | — | ||
| Q2 24 | $708.8M | — | ||
| Q1 24 | $709.0M | — |
| Q4 25 | $3.1B | — | ||
| Q3 25 | $3.0B | — | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $2.9B | $350.1M | ||
| Q4 24 | $2.8B | $229.0M | ||
| Q3 24 | $2.8B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $35.0B | — | ||
| Q3 25 | $35.1B | — | ||
| Q2 25 | $35.5B | — | ||
| Q1 25 | $34.8B | $406.9M | ||
| Q4 24 | $35.2B | $271.6M | ||
| Q3 24 | $35.8B | — | ||
| Q2 24 | $35.4B | — | ||
| Q1 24 | $35.1B | — |
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | 0.26× | — | ||
| Q1 24 | 0.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $358.6M | $131.8M |
| Free Cash FlowOCF − Capex | — | $131.7M |
| FCF MarginFCF / Revenue | — | 83.0% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $358.6M | — | ||
| Q3 25 | $99.7M | — | ||
| Q2 25 | $117.6M | — | ||
| Q1 25 | $16.4M | $131.8M | ||
| Q4 24 | $433.8M | $-23.2M | ||
| Q3 24 | $46.1M | — | ||
| Q2 24 | $135.7M | — | ||
| Q1 24 | $66.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 1.71× | — | ||
| Q1 25 | 0.28× | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.75× | — | ||
| Q2 24 | 2.53× | — | ||
| Q1 24 | 1.39× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
